Global Acute Agitation and Aggression Treatment Market - 2022-2029

Market Overview

Acute Agitation and Aggression Treatment Market are expected to grow at a CAGR of 5% during the forecasting period (2022-2029).

Agitation is characterized as excessive verbal or motor behavior in an individual. It can lead to aggression, which can be either verbal or physical. Several treatment options are available for managing acute agitation and aggression, including environmental de-escalation strategies and biological treatment options and non-pharmacologic behavioral, such as electroconvulsive therapy and pharmacologic agents. The rising prevalence of acute agitation and aggression due to workplace stress and the rising burden of mental illness are some factors that are expected to propel market growth. Moreover, the government awareness programs and increasing incidence of dementia in the geriatric population are further supporting the development of the market across the globe.

Market Dynamics: An increase in the incidence of dementia in the geriatric population continues supporting the market's growth during the forecast period.

Dementia and depression are some of the most prevalent mental and neurological disorders. Dementia affects nearly 5%, whereas depression affects almost 7% of the global elderly population. Clinical trials are currently underway to utilize this agent's properties to provide effective treatment methods for other health issues such as agitation associated with dementia of the Alzheimer's type or PTSD. The adults generally do not follow and overpower a social stigma related to mental disorders treatment. The adults frequently prefer being diagnosed and treated for mental disorders compared to the elderly population.

Moreover, increasing workplace stress is driving the growth of the global market. A major driving factor for acute agitation and aggression is increasing workplace stress. Workplace stress can have a lot of origins or come from a single event. It can affect employees as well as employers alike. According to the National Institute of Mental Health, in 2020, an estimated 52.9 million adults aged 18 or older than this in the United States with AMI. This number represented 21.0% of all U.S. adults. This prevalence of any mental illness was higher in females (25.8%) than males (15.8%). Young adults aged 18-25 years had the highest prevalence of AMI (30.6%) compared to adults aged 26-49 years (25.3%) and aged 50 and older (14.5%). Also, an increased level of stress was reported in the U.S. For instance, as per the American Institute of Stress (AIS), various studies demonstrated that job stress is a major reason for the stress among adults in the U.S., which has intensified in the last decade.

Market Segmentation: The anti-psychotics segment accounted for the highest share in global acute agitation and aggression treatment market.

Dementia and depression are some of the most prevalent mental and neurological disorders. According to World Health Organization, Dementia affects nearly 5%, whereas depression affects almost 7% of the global elderly population. Clinical trials are currently underway to utilize this agent's properties to provide effective treatment methods for other health issues such as agitation associated with dementia of the Alzheimer's type or PTSD. The adults generally do not follow and overpower a social stigma related to mental disorders treatment. The adults frequently prefer being diagnosed and treated for mental disorders compared to the elderly population.

Based on the route of administration, the acute agitation and aggression treatment market have been bifurcated into oral, intramuscular, and others. The oral segment dominated the global acute agitation and aggression treatment market in forecast period. In the acute agitation and aggression treatment market, the major route of administration is an oral treatment. Several drugs are offered by the key market players taken orally to treat acute agitation and aggression. The lack of awareness of the intramuscular treatment solutions for acute agitation and aggression further contributes to the rise in the adoption of oral treatment solutions. The intramuscular administration route is generally preferred to the subcutaneous route, especially when larger drug solutions are needed. Moreover, a longer needle is required for the intramuscular route, limiting its adoption and supporting the growth of the oral route of administration to treat acute agitation and aggression.

Geographical Penetration: North America leads the global market throughout the forecast period.

North America dominated the global acute agitation and aggression treatment market and is expected to retain its position during the forecast period. The US contributed the highest market share in the North American acute agitation and aggression treatment market. The well-developed healthcare infrastructure, including the established mental health institutions and mental health structure, supports its acute agitation and aggression treatment market. Moreover, some of the key players, such as Pfizer Inc., Janssen Biotech, Inc., and Eli Lilly and Company, are further driving the market's growth in the region.

The Asia Pacific is estimated to grow at a considerable growth rate in the acute agitation and aggression treatment market during the forecast period. This growth can be accredited to the expansion of market players in the region, considering the high investment for establishing informal healthcare infrastructure by the governments in the Asia Pacific.

Competitive Landscape:

The acute agitation and aggression treatment market is highly competitive. The key acute agitation and aggression treatment players contributing to the global market's growth include Eli Lilly and Company, Janssen Biotech, Inc. (Johnson & Johnson), Ono Pharmaceutical Co., Ltd., Mylan NV, Impel Pharmaceuticals and Pfizer Inc. The major players are adopting new product launches and expansion strategies for global growth in the acute agitation and aggression treatment market. In July 2022, Impel Pharmaceuticals Announced First Patient Dosed in Phase 2a Evaluating INP105 especially to Treat Acute Agitation in Adolescents with Autism Spectrum Disorder. INP105 is specially developed as an acute treatment for agitation in persons with autism spectrum disorder (ASD) by using Impel's proprietary Precision Olfactory Delivery (POD) technology that delivers drugs to the upper nasal space. Results of this dose are expected in Q1 2023. Also, in April 2022, BioXcel Therapeutics Announced that they got FDA Approval for IGALMI (dexmedetomidine) Sublingual Film, which is used in Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults. This approval is generally based on data from two pivotal randomized, double-blinded, placebo-controlled, parallel-group Phase 3 trials evaluating dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.

COVID-19 Impact: Negative impact on the global acute agitation and aggression treatment market.

The outbreak of COVID-19 has certainly impacted the global acute agitation and aggression treatment market, as the lockdown has compelled the diagnosis and the clinic visits of patients. The researchers' shift towards developing the COVID-19 vaccine has deterred the R&D in acute agitation and aggression treatment. Therefore, the acute agitation and aggression treatment market are expected to foresee a considerable decline in 2020.

The global acute agitation and aggression treatment market report would provide an access to approximately 61 market data tables, 52 figures and 170 pages